NYSE$AVNS

Avanos Medical Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

AVNS Q2 2024 — $13.6M revenue

The matters discussed in these forward-looking statements are based on the current plans and expectations of our management and are subject to certain risks and uncertainties that could cause actual r. Avanos Medical Inc reported Q2 2024 results. Net income of $1.8. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $13.6M.
  • Net income: $1.8.
  • Operating income: $2.1M.
  • Gross profit: $95.6.

Headline financials

Total Revenue

$172M

Previous: $169M+1.4%
EPS (adj)

$0.34

Previous: $0.24+41.7%
Capital Expenditures

-$5.9M

No prior period
Free Cash Flow

$1.8M

Previous: -$68.1M+102.6%
Net Income

$1.8M

Previous: -$68.1M+102.6%
Operating Income

$6.3M

Previous: -$2.1M+400.0%
Gross Profit

$95.6M

Previous: $97.8M-2.2%
Cash & Equivalents

$92.2M

Previous: $81.8M+12.7%
Total Assets

$1.66B

Previous: $1.67B-0.5%
R&D Expense

$6.3M

No prior period
Stock-Based Comp

$3.8M

Previous: $3.9M-2.6%

Revenue & EPS history

Avanos · Revenue · Quarterly

$172M

Q2 2024+1.4%vs Q2 2023
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-0.7%

Avg return

Earnings day

-1.1%

Avg return

5 days after

-1.7%

Avg return

30 days after

50%

25 / 50 earnings

Positive

+17.2%

Q3 2023

Best reaction

-27.6%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%+0.5%+1.3%
Q4 2025-11.0%-7.4%-9.1%
Q3 2025-1.2%-3.3%+1.4%
Q1 2025+5.6%+3.8%+1.1%
Q4 2024+0.4%-2.8%-10.3%
Q3 2024-17.5%-15.1%-15.3%
Q2 2024+3.4%-0.0%+5.5%
Q1 2024+4.7%+4.0%+6.0%
Q4 2023+1.7%+2.6%+1.6%
Q3 2023+17.2%+18.3%+20.3%
Q2 2023-2.1%-5.8%-15.4%
Q1 2023-18.7%-19.0%-14.3%
Q4 2022-2.7%-4.3%-6.5%
Q3 2022-0.1%+7.2%+20.9%
Q2 2022-1.3%+1.8%-13.4%
Q1 2022+0.9%-12.0%-3.8%
Q4 2021+15.1%+19.9%+12.2%
Q3 2021+12.8%+9.7%-4.6%
Q2 2021-11.8%-9.8%-12.5%
Q1 2021-8.2%-10.0%-8.6%
Q4 2020-14.7%-16.7%-14.0%
Q3 2020+9.2%+7.2%+17.4%
Q2 2020-0.8%+0.0%+3.1%
Q1 2020-4.2%-6.3%+10.0%
Q4 2019+7.3%+5.9%-16.4%
Q3 2019-27.6%-24.9%-30.4%
Q2 2019-3.5%+0.7%-10.4%
Q1 2019-6.3%-3.8%-13.8%
Q4 2018-6.7%-6.2%-18.4%
Q3 2018-15.5%-13.8%-21.9%
Q2 2018+9.8%+8.0%+23.4%
Q1 2018+8.0%+9.6%+15.9%
Q4 2017+2.3%-3.2%-4.5%
Q3 2017+11.5%+9.9%+14.9%
Q2 2017+6.6%+6.5%+13.6%
Q1 2017-7.0%-5.0%-6.5%
Q4 2016-5.7%-3.0%-7.7%
Q3 2016+0.7%+6.6%+16.4%
Q2 2016+5.6%+6.4%+8.1%
Q1 2016-2.2%
Q4 2015+1.7%
Q3 2015+4.6%
Q2 2015-1.1%
Q1 2014-2.4%
Q1 2015+2.2%
Q2 2014-0.3%
Q4 2012-0.3%
Q4 2014+3.7%
Q3 2014+0.7%
Q4 2013+0.7%
Q3 2013
Q2 2013
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro